Dr. Patrick Wen shares his expert insights about current diagnostic criteria and the evolving landscape of novel therapies for the treatment of these tumors.
Evolving Diagnostic and Treatment Landscape of Lower-Grade Gliomas
Patrick Wen discloses the following relationships:
Grant/Research/Clinical Trial Support: Agios, Astra Zeneca, Bayer, Blue Earth Diagnostics , Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Bigenics, Deciphera, VBI Vaccines
Speaker’s Bureau Consultant/Advisory Boards: Merck, Prime Oncology, Roche [Brain Tumor] Avastin, Agios Pharmaceuticals Inc, Bayer, Blue Earth Diagnostics, Karyopharm, Kiyatec, Deciphera, VBI Vaccines, Puma, Astra Zeneca, Immunomic Therapeutics, Vascular Biogenics, Taiho Oncology